Compare Rubicon Research with Similar Stocks
Dashboard
Low Debt Company with Strong Long Term Fundamental Strength
- The company is Net-Debt Free
With a growth in Net Profit of 17.75%, the company declared Outstanding results in Jun 26
Stock DNA
Pharmaceuticals & Biotechnology
INR 27,674 Cr (Small Cap)
96.00
38
0.09%
-0.03
19.14%
21.44
Total Returns (Price + Dividend) 
Latest dividend: 1.496583910700539 per share ex-dividend date: Aug-07-2026
Risk Adjusted Returns v/s 
Returns Beta
News
Rubicon Research Ltd is Rated Strong Buy
Rubicon Research Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 September 2026, providing investors with the latest insights into its performance and outlook.
Read full news articleRubicon Research Ltd is Rated Strong Buy
Rubicon Research Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 September 2026, providing investors with the latest insights into its performance and outlook.
Read full news articleRubicon Research Ltd is Rated Strong Buy
Rubicon Research Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 August 2026, providing investors with the most up-to-date insight into the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article Announcements 
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
29-Aug-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for General Atlantic Singapore RR Pte Ltd
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
27-Aug-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for General Atlantic Singapore RR Pte Ltd
Shareholder Meeting / Postal Ballot-Scrutinizers Report
26-Aug-2026 | Source : BSEVoting Results along with the Scrutinizers Report of the 27th Annual General Meeting of the Company held on Wednesday 26th August 2026.
Corporate Actions 
No Upcoming Board Meetings
Rubicon Research Ltd has declared 150% dividend, ex-date: 07 Aug 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 14 Schemes (7.23%)
Held by 39 FIIs (7.52%)
General Atlantic Singapore Rr Pte Ltd (35.83%)
Shivanand Shankar Mankekar Huf (13.52%)
3.46%
Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ
QoQ Growth in quarter ended Jun 2026 is 9.71% vs 29.22% in Mar 2026
QoQ Growth in quarter ended Jun 2026 is 17.75% vs 88.33% in Mar 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Nine Monthly Results Snapshot (Standalone) - Dec'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025
YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025






